Restricted accessResearch articleFirst published online 2016-04
The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic,and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells
Podocalyxin-like protein (PODXL) is a member of CD34 family proteins. It is the protein that carries many post-translational epitopes responsible for various pluripotent surface markers including TRA-1-60, TRA-1-81, GCTM2, GP200, and mAb84. However, PODXL has not attracted the attention of stem cell biologists. Here, we report several features of PODXL mRNA and protein in pluripotent stem cells. Similar to the modification-dependent pluripotent epitopes, PODXL transcripts and carrier protein are also features of pluripotency. PODXL is highly expressed in early human embryos from oocytes up to four-cell stages. During reprogramming of human cells to pluripotency, in contrast to TRA-1-60 and TRA-1-81, PODXL is activated by KLF4 at a very early time of reprogramming. Although TRA-1-60 and TRA-1-81 are completely lost upon differentiation, a residual PODXL+ population exists even after extended differentiation and they were identified by the universal human PODXL epitope 3D3. Unlike TRA-1-60 and TRA-1-81 epitopes that are unique to primate pluripotent stem cells (PSCs), PODXL carrier protein can be used as a murine surface marker. Most importantly, antibody to 3D3 epitope causes massive necrosis and apoptosis of human PSCs (hPSCs). We suggest that 3D3 antibody could be employed to eliminate the tumorigenic pluripotent cells in hPSC-derived cells for cell transplantation.
Get full access to this article
View all access options for this article.
References
1.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS and JonesJM. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
2.
YuJ, VodyanikMA, Smuga-OttoK, Antosiewicz-BourgetJ, FraneJL, TianS, NieJ, JonsdottirGA, RuottiV, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318:1917–1920.
3.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK and YamanakaS. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
4.
HuK. (2014). All roads lead to induced pluripotent stem cells: the technologies of iPSC generation. Stem Cells Dev, 23:1285–1300.
5.
HuK. (2014). Vectorology and factor delivery in induced pluripotent stem cell reprogramming. Stem Cells Dev, 23:1301–1315.
6.
BoyerLA, LeeTI, ColeMF, JohnstoneSE, LevineSS, ZuckerJP, GuentherMG, KumarRM, MurrayHL, et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122:947–956.
7.
BadcockG, PigottC, GoepelJ and AndrewsPW. (1999). The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res, 59:4715–4719.
8.
SchopperleWM and DeWolfWC. (2007). The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem cells, 25:723–730.
9.
PeraMF, Blasco-LafitaMJ, CooperS, MasonM, MillsJ and MonaghanP. (1988). Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells. Differentiation, 39:139–149.
10.
NatunenS, SatomaaT, PitkanenV, SaloH, MikkolaM, NatunenJ, OtonkoskiT and ValmuL. (2011). The binding specificity of the marker antibodies Tra-1-60 and Tra-1-81 reveals a novel pluripotency-associated type 1 lactosamine epitope. Glycobiology, 21:1125–1130.
11.
BrimbleSN, SherrerES, UhlEW, WangE, KellyS, MerrillAHJr., RobinsAJ and SchulzTC. (2007). The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem cells, 25:54–62.
12.
DraperJS, PigottC, ThomsonJA and AndrewsPW. (2002). Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat, 200:249–258.
13.
TangC, LeeAS, VolkmerJP, SahooD, NagD, MosleyAR, InlayMA, ArdehaliR, ChavezSL, et al. (2011). An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol, 29:829–834.
14.
TanHL, FongWJ, LeeEH, YapM and ChooA. (2009). mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem cells, 27:1792–1801.
15.
SchopperleWM, KershawDB and DeWolfWC. (2003). Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun, 300:285–290.
16.
KershawDB, BeckSG, WharramBL, WigginsJE, GoyalM, ThomasPE and WigginsRC. (1997). Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem, 272:15708–15714.
17.
NielsenJS and McNagnyKM. (2009). The role of podocalyxin in health and disease. J Am Soc Nephrol, 20:1669–1676.
18.
DoyonnasR, KershawDB, DuhmeC, MerkensH, ChelliahS, GrafT and McNagnyKM. (2001). Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med, 194:13–27.
19.
SizemoreS, CicekM, SizemoreN, NgKP and CaseyG. (2007). Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res, 67:6183–6191.
20.
CaseyG, NevillePJ, LiuX, PlummerSJ, CicekMS, KrumroyLM, CurranAP, McGreevyMR, CatalonaWJ, KleinEA and WitteJS. (2006). Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet, 15:735–741.
21.
HeukampLC, FischerHP, SchirmacherP, ChenX, BreuhahnK, NicolayC, ButtnerR and GutgemannI. (2006). Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology, 49:242–247.
22.
ThomasSN, SchnaarRL and KonstantopoulosK. (2009). Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol, 296:C505–C513.
23.
SomasiriA, NielsenJS, MakretsovN, McCoyML, PrenticeL, GilksCB, ChiaSK, GelmonKA, KershawDB, et al. (2004). Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res, 64:5068–5073.
24.
HayatsuN, KanekoMK, MishimaK, NishikawaR, MatsutaniM, PriceJE and KatoY. (2008). Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun, 374:394–398.
25.
LarssonA, FridbergM, GaberA, NodinB, LeveenP, JonssonG, UhlenM, BirgissonH and JirstromK. (2012). Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer, 12:282.
26.
ShaoZ, ZhangR, Khodadadi-JamayranA, ChenB, CrowleyMR, FestokMA, CrossmanDK, TownesTM and HuK. (2016). The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis. Nat Commun, 7:10869.
27.
KanduriK, TripathiS, LarjoA, MannerstromH, UllahU, LundR, HawkinsRD, RenB, LahdesmakiH and LahesmaaR. (2015). Identification of global regulators of T-helper cell lineage specification. Genome Med, 7:122.
28.
ChatterjeeA, StockwellPA, RodgerEJ, DuncanEJ, ParryMF, WeeksRJ and MorisonIM. (2015). Genome-wide DNA methylation map of human neutrophils reveals widespread inter-individual epigenetic variation. Sci Rep, 5:17328.
AndersS, PylPT and HuberW. (2015). HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics, 31:166–169.
31.
AndersS and HuberW. (2010). Differential expression analysis for sequence count data. Genome Biol, 11:R106.
32.
DilliesMA, RauA, AubertJ, Hennequet-AntierC, JeanmouginM, ServantN, KeimeC, MarotG, CastelD, et al. (2013). A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. Brief Bioinform, 14:671–683.
33.
QuinlanAR and HallIM. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 26:841–842.
34.
KentWJ, ZweigAS, BarberG, HinrichsAS and KarolchikD. (2010). BigWig and BigBed: enabling browsing of large distributed datasets. Bioinformatics, 26:2204–2207.
35.
SmythGK. (2005). Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. GentlemanR, CareyV, DudoitS, IrizarryR and HuberW eds. Springer, New York, pp 397–420.
36.
ChooAB, TanHL, AngSN, FongWJ, ChinA, LoJ, ZhengL, HentzeH, PhilpRJ, OhSK and YapM. (2008). Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells, 26:1454–1463.
37.
WegnerB, Al-MomanyA, KulakSC, KozlowskiK, ObeidatM, JahroudiN, PaesJ, BerrymanM and BallermannBJ. (2010). CLIC5A, a component of the ezrin-podocalyxin complex in glomeruli, is a determinant of podocyte integrity. Am J Physiol Renal Physiol, 298:F1492–F1503.
38.
SassettiC, TangemannK, SingerMS, KershawDB and RosenSD. (1998). Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J Exp Med, 187:1965–1975.
39.
RichardsM, TanSP, TanJH, ChanWK and BongsoA. (2004). The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem cells, 22:51–64.
40.
ZengX, MiuraT, LuoY, BhattacharyaB, CondieB, ChenJ, GinisI, LyonsI, MejidoJ, et al. (2004). Properties of pluripotent human embryonic stem cells BG01 and BG02. Stem Cells, 22:292–312.
41.
BhattacharyaB, MiuraT, BrandenbergerR, MejidoJ, LuoY, YangAX, JoshiBH, GinisI, ThiesRS, et al. (2004). Gene expression in human embryonic stem cell lines: unique molecular signature. Blood, 103:2956–2964.
42.
CaiJ, ChenJ, LiuY, MiuraT, LuoY, LoringJF, FreedWJ, RaoMS and ZengX. (2006). Assessing self-renewal and differentiation in human embryonic stem cell lines. Stem Cells, 24:516–530.
43.
BrandenbergerR, WeiH, ZhangS, LeiS, MurageJ, FiskGJ, LiY, XuC, FangR, et al. (2004). Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. Nat Biotechnol, 22:707–716.
44.
MallonBS, ChenowethJG, JohnsonKR, HamiltonRS, TesarPJ, YavatkarAS, TysonLJ, ParkK, ChenKG, FannYC and McKayRD. (2013). StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. Stem Cell Res, 10:57–66.
45.
NielsenJS and McNagnyKM. (2008). Novel functions of the CD34 family. J Cell Sci, 121:3683–3692.
46.
LeeMW, KimDS, YooKH, KimHR, JangIK, LeeJH, KimSY, SonMH, LeeSH, et al. (2013). Human bone marrow-derived mesenchymal stem cell gene expression patterns vary with culture conditions. Blood Res, 48:107–114.
47.
YanL, YangM, GuoH, YangL, WuJ, LiR, LiuP, LianY, ZhengX, et al. (2013). Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol, 20:1131–1139.
48.
ChanEM, RatanasirintrawootS, ParkIH, ManosPD, LohYH, HuoH, MillerJD, HartungO, RhoJ, et al. (2009). Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol, 27:1033–1037.
49.
ChouBK, MaliP, HuangX, YeZ, DoweySN, ResarLM, ZouC, ZhangYA, TongJ and ChengL. (2011). Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res, 21:518–529.
50.
HockemeyerD, SoldnerF, CookEG, GaoQ, MitalipovaM and JaenischR. (2008). A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell, 3:346–353.
51.
ButtaN, LarruceaS, AlonsoS, RodriguezRB, Arias-SalgadoEG, AyusoMS, Gonzalez-ManchonC and ParrillaR. (2006). Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter. BMC Mol Biol, 7:17.
52.
PalmerRE, KotsiantiA, CadmanB, BoydT, GeraldW and HaberDA. (2001). WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol, 11:1805–1809.
53.
Stanhope-BakerP, KesslerPM, LiW, AgarwalML and WilliamsBR. (2004). The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. J Biol Chem, 279:33575–33585.
54.
GuoJK, MenkeAL, GublerMC, ClarkeAR, HarrisonD, HammesA, HastieND and SchedlA. (2002). WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet, 11:651–659.
SchwartzSD, RegilloCD, LamBL, EliottD, RosenfeldPJ, GregoriNZ, HubschmanJP, DavisJL, HeilwellG, et al. (2015). Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet, 385:509–516.
57.
ChapmanAR and ScalaCC. (2012). Evaluating the first-in-human clinical trial of a human embryonic stem cell-based therapy. Kennedy Inst Ethics J, 22:243–261.
58.
MenascheP, VanneauxV, FabreguettesJR, BelA, ToscaL, GarciaS, BellamyV, FarouzY, PoulyJ, et al. (2015). Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J, 36:743–750.
59.
MenascheP, VanneauxV, HagegeA, BelA, CholleyB, CacciapuotiI, ParouchevA, BenhamoudaN, TachdjianG, et al. (2015). Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J, 36:2011–2017.
60.
SowdenJC. (2014). ESC-derived retinal pigmented epithelial cell transplants in patients: so far, so good. Cell Stem Cell, 15:537–538.
61.
FongCY, GauthamanK and BongsoA. (2010). Teratomas from pluripotent stem cells: A clinical hurdle. J Cell Biochem, 111:769–781.
62.
FongCY, PehGS, GauthamanK and BongsoA. (2009). Separation of SSEA-4 and TRA-1-60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Stem Cell Rev, 5:72–80.
63.
ShibataH, AgeyamaN, TanakaY, KishiY, SasakiK, NakamuraS, MuramatsuS, HayashiS, KitanoY, TeraoK and HanazonoY. (2006). Improved safety of hematopoietic transplantation with monkey embryonic stem cells in the allogeneic setting. Stem Cells, 24:1450–1457.
64.
TatenoH, OnumaY, ItoY, MinoshimaF, SaitoS, ShimizuM, AikiY, AsashimaM and HirabayashiJ. (2015). Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Reports, 4:811–820.
65.
RichardsM, PhoonCW, GohGT, SengEK, GuoXM, TanCM, ChanWK and LeeJM. (2014). A new class of pluripotent stem cell cytotoxic small molecules. PLoS One, 9:e85039.
66.
Vazquez-MartinA, CufiS, Lopez-BonetE, Corominas-FajaB, Oliveras-FerrarosC, Martin-CastilloB and MenendezJA. (2012). Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep, 2:964.
67.
FujikawaT, OhSH, PiL, HatchHM, ShupeT and PetersenBE. (2005). Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol, 166:1781–1791.
68.
LarruceaS, ButtaN, Arias-SalgadoEG, Alonso-MartinS, AyusoMS and ParrillaR. (2008). Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Exp Cell Res, 314:2004–2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
